Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage

. 2004 Oct 18;2004(4):CD000483. doi: 10.1002/14651858.CD000483.pub2

Study	Reason for exclusion
Mitosek‐Sabbo	In an email of 26 September 2003, Dr Mitosek‐Sabbo stated this was a randomised study.   Methods: 80 consecutive patients; first 50 underwent peri‐operative hemodilution, the remaining 30 constituted a control group.   Intervention: peri‐operative hemodilution by extracting blood and replacement by colloids aiming at a hematocrit of 0.3. Blood retransfused after operation.   Patients: WFNS I, II or III before surgery. Only 17 of 50 treatment patients and 12 of 30 controls were operated within 14 days; the remaining patients were operated more than 14 days after the SAH.   Main reasons for exclusion: probably not randomised, and most patients treated more than 14 days after SAH.

Study

Reason for exclusion

In an email of 26 September 2003, Dr Mitosek‐Sabbo stated this was a randomised study.   Methods: 80 consecutive patients; first 50 underwent peri‐operative hemodilution, the remaining 30 constituted a control group.   Intervention: peri‐operative hemodilution by extracting blood and replacement by colloids aiming at a hematocrit of 0.3. Blood retransfused after operation.   Patients: WFNS I, II or III before surgery. Only 17 of 50 treatment patients and 12 of 30 controls were operated within 14 days; the remaining patients were operated more than 14 days after the SAH.   Main reasons for exclusion: probably not randomised, and most patients treated more than 14 days after SAH.

SAH: subarachnoid haemorrhage   WFNS: World Federation of Neurological Surgeons (grading scale for subarachnoid haemorrhage)